相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
Takanori Asakura et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease A Systematic Review
Roland Diel et al.
CHEST (2018)
Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints
Thomas Schon et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease
Jotam G. Pasipanodya et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study
Jun-ichi Kadota et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis
Nakwon Kwak et al.
CLINICAL INFECTIOUS DISEASES (2017)
Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease
Kohei Fujita et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria A Review
D. Rebecca Prevots et al.
CLINICS IN CHEST MEDICINE (2015)
Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease
Hitoshi Shimomura et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2015)
Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: A propensity score analysis
Kosaku Komiya et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing Regimen
Won-Jung Koh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease
Masaki Fujita et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2012)
Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium
Chiaki Sano et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems
D. Rebecca Prevots et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection
Maeve P. Murray et al.
CLINICAL INFECTIOUS DISEASES (2008)
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy
P. A. Jenkins et al.
THORAX (2008)
In vitro and in vivo activities of novel Fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobactetium avium complex strains in Japandel
Yoshihisa Kohno et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex
H Tomioka et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium
LE Bermudez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciproffoxacin against Mycobacterium tuberculosis and mycobacterium avium complex
H Tomioka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
分享论文
